EBAMed
Ultrasound Guidance during Radio Ablation Treatment of Cardiac Arrhythmias
Ultrasound Guidance during Radio Ablation Treatment of Cardiac Arrhythmias
EBAMed is a health care startup that is revolutionizing the treatment of Cardiac Arrhythmias through its innovative Ultrasound Imaging Solution. The company, founded in 2018 and based in Switzerland, received a significant boost with a €14.35M Series A investment on 27 June 2023.
Their flagship device, CardioKit, provides a range of functionalities including target position verification, Cardiac Motion Monitoring, Respiratory Gating, and Cardiac Gating. This comprehensive system aims to enable non-invasive treatment of Cardiac Arrhythmias, promising a disruptive approach to this critical health issue.
The recent round of funding saw participation from notable investors such as LIFTT, Mayo Clinic, Occident, Panakes Partners, The European Innovation Council, and EFI Lake Geneva Ventures. With this strong backing, EBAMed is well-positioned to make a significant impact in the field of cardiac medicine and beyond.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | €14.35M | 6 |
|
27 Jun 2023 |
| Debt Financing | Fr.100.00K | 1 | FONGIT Innovation Fund | 22 Sep 2022 |
| Grant | €2.41M | 1 |
|
08 Jan 2020 |
| Seed Round | Fr.1.20M | 2 |
|
21 Aug 2019 |
| Grant | Fr.100.00K | 1 |
|
31 Oct 2018 |
No recent news or press coverage available for EBAMed.
We care about your data, and we'd love to use cookies make your experience better.
